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Abstract: Four new monoterpenoid indole alkaloids, alstrostines C–F together with thirteen known alkaloids were isolated from the 
leaves and twigs of Alstonia rostrata. All structures of new compounds were elucidated based on NMR, FTIR, UV, and MS  
spectroscopic data. Alstrostines C–E might originate from keto-enol tautomerism of preakummicine during biogenetic pathway of 
akummicine. 
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Introduction 
Monoterpenoid indole alkaloids (MIAs), including more 
than 2000 compounds, are classified to five types, corynanthe, 
strychnos, iboga, aspidosperma, and yohimbinoid, which play 
a very important role in natural medicinal history.1 The genus 
Alstonia of Apocynaceae is rich of monoterpenoid indole  
alkaloids, and eight species of the genus are distributed in 
Yunnan province.2 The phytochemical constituents of Alstonia 
sp. have been investigated intensively with anticancer,  
antibacterial, antifertility, and antitussive activity being  
reported.3 We reported new alkaloids from A. scholaris, and A. 
yunnanensis, and A. mairei recently.4 As part of systematic 
phytochemical research on Yunnan endemic resources, another 
species, A. rostrata, named Winchia calophylla in Flora of 
China,5 was also investigated. Previous studies on the stem 
bark and root of A. rostrata, collected from Yunnan Province 
of China, have reported a number of indole alkaloids and some 
nonalkaloid compounds.6 In the current study, separation of 
total alkaloids led to seventeen MIAs besides alstrostines A 
and B.7 In this paper, we will describe the isolation and  
structural elucidation of other four new alkaloids alstrostines 
C–F (1–4) together with thirteen known isolates, 19,20-
dihydroakuammicine (5), echitamidine (6), 12-
methoxyechitamidine (7), 19-oxo-12-methoxyechitamidine, 
vallesiachotamine (9), isovallesiachotamine (10), deacety-
lakuammiline (11), 17-O-acetyl-N4-demethylechitamine (12), 
N4-demethylechitamine (13), akuammidine (14), 6,7-
secoangustilobine (15), undulifoline (16), tabersonine (17). 
The biogenetic pathway of the new alkaloids was proposed. In 
addition, all compounds were tested for their cytotoxicity 
against five human cancer cell lines, but no activity was found 
(IC50 > 40 μM). 
 
Results and Discussion 
The MeOH extract of A. rostrata leaves and twigs was 
partitioned between H2O and EtOAc after acid-alkali treating, 
and column chromatography was used to separate the 
 
Figure 1.  New alkaloids from Alstonia rostrata 
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alkaloidal fraction into seventeen alkaloids. 
Alkaloid 1 gave positive reactions with Dragendorff’ 
reagent and had a molecular formula of C22H26N2O5 by 
HRESIMS at m/z 399.1919 [M + H]+. The maximum UV 
absorptions at 214, 275, and 326 nm of 1 pointed to an indole 
alkaloid with a -anilineacrylate system8 in agreement with the 
FTIR absorption bands at 3453, 1705, and 1646 cm–1. In the 
1H NMR spectrum of 1, three signals [δH 6.98 (d, J = 8.0 Hz, 
H-9), 7.13 (t, J = 8.0 Hz, H-10), 7.03 (d, J = 8.0 Hz, H-11) 
revealed the presence of a mono-subsitituted A ring in MIA.6b 
The 13C NMR and DEPT spectra of 1 indicated signals for a 
dihydroindole ring [δC 128.5 (s, C-13), 139.7 (s, C-8), 112.3 (d, 
C-11), 113.4 (d, C-9), 126.7 (d, C-10), 148.3 (s, C-12), 55.0 (s, 
C-7)]. Moreover, 1 also possessed three methylenes [δC 53.8 
(C-5), 41.6 (C-6), 48.5 (C-21)], three methines [δC 68.5 (C-19), 
59.9 (C-3), 31.5 (C-15)], one methyl (δC 20.9, C-18), and one 
sp2 quaternary carbon (δC 152.0) besides confirming presence 
of methyl β-anilineacrylate conjugation [δC 170.5 (s), 160.0 
(d), 53.8 (q), 120.1 (s)]8. The quaternary carbon signal at δC 
152.0 correlated with H-3 (δH 3.75) and H-6 (δH 1.65 and 2.82) 
in the HMBC spectrum was assigned to C-2. Detailed analysis 
of 13C NMR and DEPT data revealed 1 might be belong to 
akuammicine-type alkaloids. Further NMR comparison with 
those of 12-methoxyechitamidine (7)9 indicated that 1 was 
similar to 7 with exception for an additional methine (δC 160.0 
and δH 9.12) in 1. The methine proton showed HMBC 
correlation to C-2, suggesting that the methine was connected 
with C-2 by an oxygen bridge with consideration of its 
molecular formula. 
The UV spectrum of 2 and 3 also indicated the absorption 
bands of indole rings with a -anilineacrylate system together 
with FTIR spectrum. Compound 2 was found to possess a 
molecular formula of C22H24N2O5 as evidenced by HRESIMS 
at m/z 397.1763 [M + H]+, an additional degree of unsaturation 
to 1. The 1H NMR spectra of 2 also displayed the signals for 
mono-substituted indole ring [δH 7.00 (d, J = 7.9 Hz, H-9), 
7.05 (d, J = 7.9 Hz, H-11), 7.16 (t, J = 7.9 Hz, H-10). Its 13C 
NMR and DEPT data showed similar pattern to 1 (see Table 1) 
except that the methine of C-19 was disappeared, instead a 
new signal of carbonyl group (δC 207.2, s) was present in 2. Its 
HMBC correlations could support it, in which δH 2.24 (H-18) 
was correlated with δC 207.2 (C-19) and 50.6 (C-18). 
Compound 3 possessed a molecular formula of C22H24N2O4 
based on the HRESIMS. The 1H and 13C NMR spectra of 3 
displayed similarity to 1 except for two methine signals at δC 
68.5 (C-19) and 47.3 (C-20) in 1 were substituted by double 
bond signals (δC 136.1 and 119.8) in 3, suggesting that 3 was a 
dehydration product of 1. 
Configuration of alkaloids 1–3 was determined by NMR 
and ROESY spectra together with their biogenetic pathway. 
The chemical shift of C-19 in 1 was deshielded (Δ2.6 ppm) 
similar to N4-demethyl-12-methoxyalstogustine and N4-
demethylalstogustine, relative to 12-methoxyechitamidine and 
echitamidine due to intramolecular H-bonding between the 
nitrogen atom and the C-19-OH.6a The ROESY correlations of 
H-3 with H-15 and H-20 in 1–3 placed them on the same sides. 
The double bond C-19/20 of 3 was determined as E according 
the ROESY correlation of H-19 with H-21. In the biogenetic 
pathway of akummicine,10 the keto-enol tautomerism among 
O-C17-C16 of preakuammicine would give two reaction routes, 
which led to alstrostines C–E and akummicine, respectively 
(Fig. 2). Hence, configurations of alstrostines C–E were same 
to akummicine, as shown in Fig. 1. 
HRESIMS at m/z 603.2553 [M + H]+ defined molecular 
formula of compound 4 as C30H38N2O11. The IR spectrum of 4 
implied the presence of hydroxyls (3424 cm–1), double bonds 
(1627 cm–1), and carbonyl groups (1703 cm–1). Its UV 
spectrum showed the characteristic absorption bands of indole 
alkaloids at 226 and 282 nm11 in agreement with 1H NMR 
signals at δH 7.39 (1H, d, J = 7.8 Hz), 7.28 (1H, d, J = 7.8 Hz), 
 
Figure 2.  Proposed biogenetic pathway of alstrostines C–E  
skeleton 
Table 1. 13C NMR spectroscopic data for compounds 1–4 (1–3 
in acetone-d6, 4 in methanol-d4, δ in ppm, J in Hz) 
carbon 1 2 3 4 
2 152.0 s 152.0 s 152.0 s 136.1 s 
3 59.9 d 59.9 d 60.5 d 58.6 d 
5 53.8 t 53.8 t 54.1 t 44.5 t 
6 41.6 t 41.5 t 42.1 t 17.5 t 
7 55.0 s 55.1 s 55.3 s 107.5 s 
8 139.7 s 139.5 s 139.8 s 128.2 s 
9 113.4 d 113.3 d 113.6 d 118.5 d 
10 126.7 d 126.8 d 126.6 d 119.4 d 
11 112.3 d 112.4 d 112.3 d 121.7 d 
12 148.3 s 148.2 s 148.4 s 111.7 d 
13 128.5 s 128.5 s 128.5 s 137.2 s 
14 30.6 t 31.1 t 30.1 t 36.3 t 
15 31.5 d 33.4 d 32.5 d 30.6 d 
16 120.1 s 119.3 s 119.8 s 112.7 s 
17 160.0 d 159.8 d 159.8 d 152.7 d 
18 20.9 q 28.6 q 12.8 q 119.0 t 
19 68.5 d 207.2 s 119.8 d 135.7 d 
20 47.3 d 50.6 d 136.1 s 45.8 d 
21 48.5 t 46.3 t 54.5 t 97.1 d 
22 170.5 s 167.0 s 167.1 s 168.3 s 
23    55.7 t 
24    172.9 s 
12-OMe 55.0 q 56.2 q 56.2 q  
22-OMe 53.8 q 51.7 q 12-OMe 51.5 q 
24-OMe    51.8 q 
1'    99.4 d 
2'    74.7 d 
3'    77.7 d 
4'    71.5 d 
5'    78.4 d 
6'    62.5 t 
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7.01 (1H, t, J = 7.8 Hz), 6.96 (1H, d, J = 7.8 Hz). Its 13C NMR 
and DEPT spectra displayed six methylenes (δC 119.0, 62.5, 
55.7, 44.5, 36.3, 17.5), fourteen methines (δC 152.7, 135.7, 
121.7, 119.4, 118.5, 111.7, 99.4, 97.1, 78.4, 77.7, 74.7, 71.5, 
58.6, 45.8, 30.6), seven quaternary carbons (δC 136.1, 107.5, 
128.2, 137.2, 112.7, 168.3, 172.9), and two methoxyls (δC 51.8, 
51.5). Above data were similar to those of strictosidine12 with 
exception for additional methylene (δC 55.7, t) and 
methoxycarbonyl [δC 172.9 (s) and 51.8 (q)] in 4. In the 
HMBC spectrum, both H-3 (δH 4.07) and H-5 (δH 3.08 and 
3.12) were correlated with δC 55.7 (t), suggesting the 
methylene was connected with N4. In addition, the methylene 
protons (δH 3.47 and 3.60) showed correlations to 172.9 (s), 
indicating 4 was strictosidine methyl N4-acetate. 
All alkaloids 1–17 were tested for their ability to prevent the 
cytopathic effects of cancer in breast cancer SK-BR-3,  
hepatocellular carcinoma SMMC-7721, human myeloid  
leukemia HL-60, pancreatic cancer PANC-1, and lung cancer 
A-549 cells, and their cytotoxicity was measured in parallel 
with the determination of antitumor activity using cisplatin as 
the positive control. Unfortunately, none of them showed  
positive activity (IC50 > 40 μM). 
 
Experimental Section 
General Experimental Procedures. Optical rotations were 
measured with a Horiba SEAP-300 spectropolarimeter. UV 
spectra were recorded on a Shimadzu double-beam 210A  
spectrophotometer. IR (KBr) spectra were obtained on  
Bio-Rac. FTS-135 infrared spectrophotometer. 1H, 13C and 2D 
NMR spectra were recorded on a AM-400 and DRX-500 MHz 
NMR spectrometer with TMS as an internal standard. MS data 
were obtained on an API Qstar Pulsar I spectrometer. Silica 
gel (200–300 mesh) for column chromatography (CC) and 
GF254 for TLC were obtained from Qingdao Marine Chemical 
Factory, Qingdao, China and sprayed with Dragdorff’ reagent. 
C18 silica gel (20–45 μm) was bought from Fuji Chemical 
Ltd., Japan. MPLC was employed Buchi pumps system cou-
pled with glass column (15 × 230 and 26 × 460 mm, respec-
tively, C18 silica gel). HPLC was performed using Waters 600 
pumps coupled with analytical and semipreparative sunfire 
C18 columns (150 × 4.6 and 150 × 10 mm, respectively). The 
HPLC system employed a Waters 2996 photodiode array  
detector and a Waters fraction collector II. 
 
Plant Material. Alstonia rostrata C. E. C. Fischer was  
colleted in Apr. 2010 in Simao of Yunnan Province, China, 
and identified by Dr. Chun-Xia Zeng. Voucher specimen 
(Cai100613) deposited in the State Key Laboratory of  
Phytochemistry and Plant Resources in West China, Kunming 
Institute of Botany, the Chinese Academy of Sciences. 
 
Extraction and Isolation. Air-dried leaves and twigs (8.0 
kg) of A. rostrata was crushed and extracted with EtOH (20 L 
× 3). After removal of the EtOH under reduced pressure, the 
residue was dissolved in 1% HCl, and partitioned with EtOAc 
for three times. The acidic solution was subsequently basified 
using ammonia water to pH 8~9, and partitioned with EtOAc 
for three times, affording a two-phase mixture including the 
aqueous phase, EtOAc/organic phase (total alkaloids). The 
Table 2. 1H NMR spectroscopic data for compounds 1–4 (1–3 in acetone-d6, 4 in methanol-d4, δ in ppm, J in Hz) 
C δH (1) δH (2) δH (3) δH (4) 
N1    9.65 (1H, br. s) 
3 3.75 (1H, br. s) 3.78 (1H, t, 2.6) 3.88 (1H, t, 2.6) 4.07 (1H, t, 6.0)  
5 2.82 (2H, m) 2.82 (1H, m); 2.98 (1H, m) 2.79 (1H, m); 2.98 (1H, m) 3.08 (1H, m); 3.12 (1H, m) 
6 1.65 (1H, m); 2.82 (1H, m) 1.68 (1H, m); 2.85 (1H, m) 3.10 (1H, m); 3.37 (1H, m) 2.78–2.81 (1H, m); 2.46 (1H, dd, 4.8, 4.5 ) 
9 6.98 (1H, d, 8.0) 7.00 (1H, d, 7.9) 7.02 (1H, d, 7.4) 7.39 (1H, d, 7.8) 
10 7.13 (1H, t, 8.0) 7.16 (1H, t, 7.9) 7.15 (1H, t, 7.4) 7.01 (1H, t, 7.8) 
11 7.03 (1H, d, 8.0) 7.05 (1H, d, 7.9) 7.07 (1H, d, 7.4) 6.96 (1H, t, 7.8) 
12    7.28 (1H, d, 7.8) 
14 1.47 (2H, m) 1.52 (1H, m); 2.11 (1H, m) 1.50 (1H, m); 2.06 (1H, m) 1.86 (2H, m) 
15 3.01 (1H, m) 3.30 (1H, m) 3.69 (1H, m) 3.63 (1H, m) 
17 9.12 (1H, s) 9.06 (1H, s) 9.12 (1H, s) 7.45 (1H, s) 
18 1.11 (3H, d, 6.2) 2.24 (3H, s) 1.72 (3H, d, 7.2) 5.75 (2H, m) 
19 3.44 (1H, m)  5.45 (1H, q, 7.2) 5.36 (1H, m) 
20 1.65 (1H, m) 2.90 (1H, m)  2.70 (1H, m) 
21 2.03 (1H, m); 2.80 (1H, m) 2.53 (1H, m); 2.80 (1H, m) 3.10 (1H, d, 13.4); 3.37 (1H, d, 13.4) 5.49 (1H, d, 5.5) 
23    3.47 (1H, d, 16.5); 3.60 (1H, d, 16.5) 
12-OMe 3.95 (3H, s) 3.93 (3H, s) 3.98 (3H,s)  
22-COOMe 3.67 (3H, s) 3.60 (3H, s) 3.67 (3H,s) 3.68 (3H,s) 
24-COOMe    3.65 (3H,s ) 
1'    4.74 (1H, d, 7.8) 
2'    3.27 (1H, overlap) 
3'    3.43 (1H, overlap) 
4'    3.35 (1H, m) 
5'    3.35 (1H, overlap) 
6'    3.81 (1H, d, 12.8); 3.63 (1H, overlap) 
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total alkaloid fraction (78 g) was collected and then dissolved 
in MeOH, and was subjected to column chromatography over 
silica gel eluting with CHCl3-MeOH [from CHCl3 to CHCl3-
MeOH (1:1)] to afford six fractions (I–VI) according to  
differences in composition monitored by TLC plate after 
spraying with dragendorff’s reagent. Fraction I was further 
purified by column chromatography on silica gel (35 g) using 
petroleum ether-Me2CO (9:1) to give 17 (220 mg). Fraction II 
(4.5 g) was subjected to MPLC over RP18 gel (52 g) column, 
eluting with MeOH-H2O (from 2:8 to 9:1) to afford six  
subfractions (II-1~II-6). Fraction II-2 (2.5 g) was further  
purified by column chromatography on silica gel (35 g) using 
CHCl3-Me2CO (9:1~4:1) to give 2 (220 mg), II-2-2 (45 mg) 
and II-2-3 (1.6 g). II-2-2 was seprarted by semipreparative 
reversed-phase C18 HPLC on Xterra column with gradient 
flow from 35% to 65% aquous methanol to affort pure  
compound 1 (30 mg). II-2-2-3(100 mg) was subjected to 
MPLC over C18 gel (26 g) column, eluting with MeOH-H2O 
(from 2:3 to 7:3) to afford pure compound 6 (300 mg) and 7 
(50 mg). Fraction II-5 (300 mg) was further purified by semi-
preparative column with gradient flow from 50 to 75% aquous 
methanol to give 3 (40 mg). Same semipreparative column 
with gradient flow from 40 to 60% aquous methanol was used 
to separate combination of subfractions II-6 (70 mg) .This 
technique afforded 5 (25 mg). Fr.III (1.5 g) was subjected on 
C18 silica gel CC and eluted with 30–80% aquous methanol to 
give 6 subfractions III-1~6. Fraction III-3 (200 mg) was loaded
on silica gel (20 g) CC eluting by petroleum CHCl3-Me2CO 
(from 6:1 to 4:1) to obtain 8 (18 mg). Fraction III-5 (50 mg) 
were subjected to a C18 semipreparative column and eluted 
with 50–80% aquous methanol to afford compound 4 (5 mg). 
Fraction III-6 (800 mg) were subjected to a C18 semiprepara-
tive column and eluted with 40–80% aquous methanol to af-
ford 9 (13 mg) and 12 (40 mg). Fr.IV (6.5g) was subjected on 
C.C. over Rp-18 silica gel (160 g) and eluted with 40–100% 
methanol to affort subfractions IV-1~5. Fraction IV-1 (1.15 g) 
was rechromatographed on a Si gel (30 g) column and eluted 
with petroleum CHCl3-Me2CO (from 3:1 to 1:1) to give 10 (11 
mg) and 16 (70 mg). Fraction IV-3 (1.9 g) was rechromato-
graphed on a C18 Si gel (50 g) column and eluted with 50% 
aquous methnal to give 13 (28 mg) and 14 (36 mg). Fraction 
IV-5 (50mg) was further purified by column chromatography 
on silica gel (5 g) using CHCl3-Me2CO (2:1~1:1) to give  
alkaloid 15 (4 mg). Alkaloid 11 (600 mg) is acrystal from  
fraction V. 
 
Alstrostine C (1): C22H26N2O5, yellow powder. [α]18D   +47 (c 
0.16, MeOH). UV (MeOH): 214 (3.95), 275 (3.26), 326 (3.02); 
IR (KBr): 3453, 2939, 1705, 1646, 1366 cm–1; 1H NMR (400 
MHz) and 13C NMR (100 MHz), see Tables 1 and 2, respec-
tively. Positive ESIMS m/z: 399 [M + H]+, HRESIMS m/z: 
399.1915 [M + H]+ (calcd. for C22H27N2O5 399.1919). 
 
Alstrostine D (2): C22H24N2O5, yellow powder. [α]18D   +41.8 
(c 0.15, CH3OH); UV (MeOH): 211 (4.03), 274 (3.27), 326 
(3.11); IR (KBr): 3432, 2928, 1709, 1694, 1644 cm–1; 1H (400 
MHz) and 13C NMR (100 MHz), see Tables 1 and 2,  
respectively. Positive ESIMS m/z: 397 [M + H]+; HRESIMS 
m/z: 397.1756 [M + H]+ (calcd. for C22H25N2O5 397.1763). 
 
Alstrostine E (3): C22H24N2O4, yellow powder. [α]18D   +193 
(c 0.11, MeOH); UV (MeOH): 213 (3.93), 274 (3.15), 326 
(3.03) nm; IR (KBr): 3432, 2946, 1696, 1654, 1452, 1359 cm–1; 
1H NMR (400 MHz) and 13C NMR (100 MHz), see Tables 1 
and 2, respectively. Positive ESIMS m/z: 381 [M + H]+, 
HRESIMS m/z: 381.1820 [M + H]+ (calcd. for C22H25N2O4 
381.1814). 
 
Alstrostine F (4): C30H38N2O11, white powder. [α]19D   –70 (c 
0.11, MeOH). UV (MeOH): 226 (3.96), 282 (3.14) nm; IR 
(KBr): 3424, 2924, 1703, 1627, 1075 cm–1; 1H NMR (500 
MHz) and 13C NMR (100 MHz), see Tables 1 and 2,  
respectively. Positive ESIMS m/z: 603 [M + H]+, HRESIMS 
m/z: 603.2536 [M + H]+ (calcd. for C30H39N2O11 603.2553). 
 
Cytotoxicity Assay. Five human cancer cell lines, breast 
cancer SK-BR-3, hepatocellular carcinoma SMMC-7721,  
human myeloid leukemia HL-60, pancreatic cancer PANC-1, 
and lung cancer A-549 cells, were used in the cytotoxic assay. 
All the cells were cultured in RPMI-1640 or DMEM medium 
(Hyclone, USA), supplemented with 10% fetal bovine serum 
(Hyclone, USA) in 5% CO2 at 37 C. The cytotoxicity assay 
was performed according to the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) method in 96-well 
microplates.13 Briefly, 100 µL adherent cells were seeded into 
each well of 96-well cell culture plates and allowed to adhere 
for 12 h before drug addition, while suspended cells were 
seeded just before drug addition with initial density of 1 × 105 
cells/ml. Each tumor cell line was exposed to the test  
compound at concentrations of 0.0625, 0.32, 1.6, 8, and 40 μm 
in triplicates for 48 h, with cisplatin (sigma, USA) as the  
positive control. After compound treatment, cell viability was 
detected and cell growth curve was graphed. IC50 value was 
calculated by Reed and Muench’s method.14 
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